Data from the Surveillance Epidemiology of Coronavirus under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) registry confirmed our findings, as 40% of patients discontinued anti-tumor necrosis factor alpha (TNF-α) therapy after COVID-19 diagnosis and 62% discontinued anti-TNF-α and immunomodulator combination therapy [19]. The gene discussed is TNF; the disease is inflammatory bowel disease.